Abstract
Recent years has seen much interest and attention turned to the subject of thrombosis, with an appreciation of the incidence and significance of the process in cardiovascular disease, improved understanding of the pathogenesis of the process and interrelated circumstances, development of new approaches to therapy, and the mechanism of action of various forms of treatment. The thrombotic process is involved as a primary event in the pathogenesis of many cardiac or vascular diseases, or in the complications associated with pathologic conditions of other etiologies. An understanding of thrombosis is important for clinicians managing patients with cardiovascular conditions in order to understand the predisposing factors and prognosis of the conditions. Perhaps more importantly, such understanding allows appreciation of the alternatives for therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Thrombogenesis
Hirsh J, Genton E: Thrombogenesis. In: Physiological pharmacology. Vol. V, Root WS, Berlin NI (eds). New York, Academic Press, Inc., 1974, p 99–133.
Mustard JF, Packham MA: Platelets, thrombosis and drugs. In: Antithrombotic drugs, Vol 3, Avery GS (ed), Sydney, Australasian Drug Information Services, 1977, p 1–83.
Anticoagulants
Kakkar VV, Thomas DP: Heparin chemistry and clinical usage, New York, Academic Press, Inc., 1976.
Fratantoni J, Wessler S: Prophylactic therapy of deep vein thrombosis and pulmonary embolism, Washington, D.C., DHEW Publication No. (NIH) 76–866; U.S. Government Printing Office, 1976.
Gallus AS, Hirsh J: Antithrombotic drugs: Parts I & II. Drugs 12: 41–68 and 132–157, 1976.
Rogers PH, Sherry S: Current status of antithrombotic therapy in cardiovascular disease. Progr Cardiov Dis 19: 235–253, 1976.
Fenech A, Winter JH, Douglas AS: Individualisation of oral anticoagulant therapy. Drugs 18: 48–57, 1979.
Platelet Drugs
Genton E, Gent M, Hirsh J, Harker AL: Platelet-inhibiting drugs in the prevention of clinical thrombotic disease. New Eng J Med 293: 1174–1178, 1236–1240 and 1296–1300, 1975.
Turpie AGG, Hirsh J: Platelet suppressant therapy. In: Venous and Arterial Thrombosis: Pathogenesis, Diagnosis, Prevention, and Therapy, Joist JH, Sherman LA (eds), New York, Grune and Stratton, Inc., 1979, p 339–363.
Genton E, Barnett HJM, Fields WS, Gent M, Hoak JC: Cerebral ischemia: the role of thrombosis and of antithrombotic therapy. Stroke 8: 147–175, 1977.
Thrombolytic Drugs
Sonnenblick EH, Lesch M: Fibrinolysis. I & II. Progr Cardiov Dis 12 (4 and 5): 239–313 and 315–403, 1979.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Martinus Nijhoff Publishers bv, The Hague
About this chapter
Cite this chapter
Genton, E. (1980). Antithrombotic Drugs. In: Dreifus, L.S., Brest, A.N. (eds) Clinical Applications of Cardiovascular Drugs. Developments in Cardiovascular Medicine, vol 5. Springer, Dordrecht. https://doi.org/10.1007/978-94-010-9178-7_8
Download citation
DOI: https://doi.org/10.1007/978-94-010-9178-7_8
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-247-2369-0
Online ISBN: 978-94-010-9178-7
eBook Packages: Springer Book Archive